AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33720787 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one PRISM-P intervention
Number of subjects: 94
Study 33720787 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PRISM-P intervention
Number of subjects: 94
Study 33720787 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 94
Study 32977595 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week intensive diet-exercise intervention (Phase 1)
Number of subjects: 0
Study 32977595 — intervention group
Group type: EXPERIMENTAL
Intervention: Free living conditions supervision (Phase 2)
Number of subjects: 0
Study 35637457 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography (US)
Number of subjects: 200
Study 35637457 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic bronchoscopy (FOB)
Number of subjects: 200
Study 35275165 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (exposed group)
Number of subjects: 828
Study 35275165 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone or Methylprednisolone (exposed group)
Number of subjects: 828
Study 35275165 — intervention group
Group type: COMPARATOR
Intervention: Control group (unexposed infants)
Number of subjects: 828
Study 34331551 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg twice daily for 1 month
Number of subjects: 238
Study 34331551 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 100 mg once daily
Number of subjects: 238
Study 34331551 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 50 mg twice daily, 75 mg once daily, 50 mg once daily
Number of subjects: 238
Study 34331551 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen 100 mg twice daily
Number of subjects: 238
Study 34331551 — intervention group
Group type: COMPARATOR
Intervention: Aspirin given every second or third day
Number of subjects: 238
Study 34331551 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 238
Study 33321007 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite-conditioned reflex stimulation (visual, nasal, taste, and hearing stimulation)
Number of subjects: 70
Study 33321007 — intervention group
Group type: EXPERIMENTAL
Intervention: Appetite-conditioned reflex stimulation
Number of subjects: 70
Study 33321007 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard early enteral nutrition)
Number of subjects: 70
Study 33781724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh corneal graft carrier
Number of subjects: 19
Study 33781724 — intervention group
Group type: COMPARATOR
Intervention: Frozen corneal graft carrier
Number of subjects: 19
Study 32892250 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 74
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy area in the central 1-mm diameter zone
Number of subjects: 365
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: GA area in the temporal region
Number of subjects: 365
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: GA area in the superior region
Number of subjects: 365
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: VA decline rate in eyes with initial noncentral GA
Number of subjects: 365
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: VA decline rate in eyes with initial central GA
Number of subjects: 365
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: Total GA area
Number of subjects: 365
Study 33212271 — intervention group
Group type: EXPERIMENTAL
Intervention: GA area in the central zone
Number of subjects: 365
Study 32166994 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan-based regimens
Number of subjects: 34
Study 32166994 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (Cy)-total body irradiation (TBI)-based regimens
Number of subjects: 34
Study 35597471 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine (5-20 mg/day)
Number of subjects: 5982
Study 33358648 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTA VCD (Teleflex)
Number of subjects: 210
Study 33358648 — intervention group
Group type: COMPARATOR
Intervention: ProGlide (Abbott Vascular)
Number of subjects: 210
Study 32616272 — intervention group
Group type: EXPERIMENTAL
Intervention: 20L:4D
Number of subjects: 432
Study 32616272 — intervention group
Group type: EXPERIMENTAL
Intervention: 18L:6D
Number of subjects: 432
Study 32616272 — intervention group
Group type: EXPERIMENTAL
Intervention: 16L:8D
Number of subjects: 432
Study 32616272 — intervention group
Group type: EXPERIMENTAL
Intervention: 12L:12D
Number of subjects: 432
Study 35209877 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART Choice tool
Number of subjects: 0
Study 35209877 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 0
Study 34488408 — intervention group
Group type: EXPERIMENTAL
Intervention: Six-month anti-TB therapy
Number of subjects: 80
Study 34488408 — intervention group
Group type: COMPARATOR
Intervention: Nine-month anti-TB therapy
Number of subjects: 80
Study 34488408 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 35892319 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted training
Number of subjects: 172
Study 35892319 — intervention group
Group type: COMPARATOR
Intervention: Enhanced upper extremity therapy
Number of subjects: 172
Study 35892319 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 172
Study 33360679 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK120067 (oral irreversible tyrosine kinase inhibitor)
Number of subjects: 0
Study 33360679 — intervention group
Group type: EXPERIMENTAL
Intervention: ASK120067 (oral administration)
Number of subjects: 0
Study 35413023 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 120
Study 35413023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33788609 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapies (acetaminophen, NSAIDs, opioids, benzodiazepines, Gabapentin, Neurontin, cortisone injections)
Number of subjects: 545
Study 33788609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondrug therapies (self-care treatments, massage, acupuncture, spinal manipulation, physical therapy)
Number of subjects: 545
Study 33788609 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment recommendations
Number of subjects: 545
Study 33788609 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to treatment recommendations
Number of subjects: 545
Study 35160276 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-enriched drink (NutriciaTM Pre-op®) 400 mL
Number of subjects: 100
Study 35160276 — intervention group
Group type: COMPARATOR
Intervention: Fasting (Control group)
Number of subjects: 100
Study 32842315 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg of CpG ODN recombinant (Hansenula polymorpha) Hepatitis B vaccine
Number of subjects: 48
Study 32842315 — intervention group
Group type: COMPARATOR
Intervention: 10 μg of commercial Hepatitis B vaccine
Number of subjects: 48
Study 36233749 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral anodal tDCS (20-min session, 1.5 mA, 3 times a week for 2 weeks)
Number of subjects: 84
Study 36233749 — intervention group
Group type: COMPARATOR
Intervention: Control group (tDCS current delivered for 30 seconds)
Number of subjects: 84
Study 35229141 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 101
Study 35229141 — intervention group
Group type: COMPARATOR
Intervention: Control (abiraterone or enzalutamide)
Number of subjects: 101
Study 32669957 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS protocol
Number of subjects: 129
Study 32669957 — intervention group
Group type: COMPARATOR
Intervention: Conventional postoperative care regimen
Number of subjects: 129
Study 33806310 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab added to standard of care
Number of subjects: 0
Study 33806310 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab alone or as part of combination regimens
Number of subjects: 0
Study 33806310 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 0
Study 34787471 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of burdens of participation in a clinical trial for advanced melanoma patients.
Number of subjects: 14
Study 34787471 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing capacity to cope with trial burdens.
Number of subjects: 14
Study 34418903 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg orally for 2 weeks, taken half an hour before bedtime in low light conditions)
Number of subjects: 31
Study 34418903 — intervention group
Group type: COMPARATOR
Intervention: Control (regular medications)
Number of subjects: 31
Study 34418903 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin
Number of subjects: 31
Study 32403158 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprapubic externalized single J stents (N = 100)
Number of subjects: 200
Study 32403158 — intervention group
Group type: COMPARATOR
Intervention: No stent (N = 100)
Number of subjects: 200
Study 36202129 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced usual care plus psychosocial intervention (17-week program based on psychoeducation and behavioral activation)
Number of subjects: 715
Study 36202129 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (control group)
Number of subjects: 715
Study 32909274 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene-panel next-generation sequencing (NGS) (32–55 genes)
Number of subjects: 296
Study 32909274 — intervention group
Group type: COMPARATOR
Intervention: Sanger sequencing (one to four genes)
Number of subjects: 296
Study 32909274 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 296
Study 33025372 — intervention group
Group type: EXPERIMENTAL
Intervention: Group intervention combining self-hypnosis and self-care
Number of subjects: 95
Study 33025372 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLCG)
Number of subjects: 95
Study 33249881 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing DBP increments
Number of subjects: 47407
Study 33249881 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear MR analyses
Number of subjects: 47407
Study 35965311 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel control mechanism using electromyography surface sensors applied to temporalis muscles
Number of subjects: 4
Study 35965311 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impression of Change survey
Number of subjects: 4
Study 32251176 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg)
Number of subjects: 48
Study 32251176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 36483298 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Training
Number of subjects: 30
Study 36483298 — intervention group
Group type: COMPARATOR
Intervention: Control (Physical Education Course)
Number of subjects: 30
Study 32593936 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch injury (ESI) via office hysteroscopy
Number of subjects: 184
Study 32593936 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 184
Study 34705072 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of PRP (n: 62)
Number of subjects: 237
Study 34705072 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of PRP (n: 63)
Number of subjects: 237
Study 34705072 — intervention group
Group type: COMPARATOR
Intervention: Single dose of sodium saline (NS) (n: 59)
Number of subjects: 237
Study 34705072 — intervention group
Group type: COMPARATOR
Intervention: Three doses of sodium saline (NS) (n: 53)
Number of subjects: 237
Study 33955231 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP goal achievement in women
Number of subjects: 894
Study 33955231 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP goal achievement in men
Number of subjects: 894
Study 32928185 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with supporting materials
Number of subjects: 17
Study 32928185 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with access to support groups
Number of subjects: 17
Study 32928185 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 17
Study 36175102 — intervention group
Group type: EXPERIMENTAL
Intervention: One anastomosis gastric bypass (OAGB)
Number of subjects: 248
Study 36175102 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 248
Study 36175102 — intervention group
Group type: EXPERIMENTAL
Intervention: OAGB
Number of subjects: 248
Study 36175102 — intervention group
Group type: COMPARATOR
Intervention: RYGB
Number of subjects: 248
Study 33579594 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor shopping
Number of subjects: 87
Study 33579594 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacy shopping
Number of subjects: 87
Study 33579594 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosage
Number of subjects: 87
Study 33579594 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 87
Study 33579594 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant benzodiazepine use
Number of subjects: 87
Study 36210434 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated digital intervention (ART medication messages, medication reminders, peer education, online discussion)
Number of subjects: 576
Study 36210434 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one instant message-based intervention
Number of subjects: 576
Study 36210434 — intervention group
Group type: COMPARATOR
Intervention: Control arm (messages on health behavior and nutrition)
Number of subjects: 576
Study 36210434 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 576
Study 32813124 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest shielding (using food grade aluminium foil on the left side of the chest during phototherapy)
Number of subjects: 0
Study 32813124 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 0
Study 32813124 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest shielding
Number of subjects: 0
Study 32813124 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 35157963 — intervention group
Group type: EXPERIMENTAL
Intervention: MPFL reconstruction
Number of subjects: 8
Study 35157963 — intervention group
Group type: EXPERIMENTAL
Intervention: MQTFL reconstruction
Number of subjects: 8
Study 35157963 — intervention group
Group type: COMPARATOR
Intervention: MPFC-deficient control state
Number of subjects: 8
Study 34114132 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMQOL
Number of subjects: 490
Study 34114132 — intervention group
Group type: EXPERIMENTAL
Intervention: DEMQOL-U
Number of subjects: 490
Study 32652799 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (30E% protein)
Number of subjects: 19
Study 32652799 — intervention group
Group type: COMPARATOR
Intervention: Low-protein diet (10E% protein)
Number of subjects: 19
Study 36046209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sangdantongluo granule
Number of subjects: 132
Study 36046209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 34543722 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) targeting a 25% reduction in energy intake
Number of subjects: 144
Study 34543722 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum (AL) control group
Number of subjects: 144
Study 34543722 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs9939609 SNP
Number of subjects: 144
Study 34543722 — intervention group
Group type: EXPERIMENTAL
Intervention: FTO rs9939609 SNP in AAs
Number of subjects: 144
Study 34134469 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended maintenance with subcutaneous rituximab, n=138
Number of subjects: 692
Study 34134469 — intervention group
Group type: COMPARATOR
Intervention: Observation only, n=138
Number of subjects: 692
Study 32761890 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1200
Study 32761890 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 1200
Study 35979052 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nutrition management intervention based on mobile medical APP
Number of subjects: 80
Study 33601718 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-rTMS over the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 33601718 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation over the right dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 0
Study 36156932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral endoscopic myotomy (POEM)
Number of subjects: 40
Study 36156932 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic myotomy and partial fundoplication (LM-PF)
Number of subjects: 40
Study 33782116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to left-leaning media (HuffPost)
Number of subjects: 1037
Study 33782116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to right-leaning media (Fox News)
Number of subjects: 1037
Study 33782116 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (left-leaning and right-leaning media)
Number of subjects: 1037
Study 34176293 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest tertile of systolic blood pressure variability (BPV)
Number of subjects: 19114
Study 32641226 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/Valsartan (S/V) titrated to 97 mg/103 mg twice daily
Number of subjects: 400
Study 32641226 — intervention group
Group type: COMPARATOR
Intervention: Valsartan 160 mg twice daily
Number of subjects: 400
Study 35146554 — intervention group
Group type: EXPERIMENTAL
Intervention: Proficiency-based VR training
Number of subjects: 22
Study 35146554 — intervention group
Group type: COMPARATOR
Intervention: Repetition-based VR training
Number of subjects: 22
Study 35146554 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cohort (both groups)
Number of subjects: 22
Study 34496085 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics (2g amoxicillin preoperatively and 500mg tid for 7 days postoperatively)
Number of subjects: 38
Study 34496085 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same preoperative dose of amoxicillin and placebo postoperatively)
Number of subjects: 38
Study 34496085 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain severity assessment
Number of subjects: 38
Study 34496085 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant survival rate
Number of subjects: 38
Study 33248858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking
Number of subjects: 6
Study 33248858 — intervention group
Group type: COMPARATOR
Intervention: Unassisted walking
Number of subjects: 6
Study 33248858 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton training
Number of subjects: 6
Study 33248858 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training walking with the exoskeleton
Number of subjects: 6
Study 32224896 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Cisplatin (80 mg/m2 weekly + 20 mg/m2 triweekly cisplatin)
Number of subjects: 40
Study 32224896 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Carboplatin (80 mg/m2 weekly + AUC 5 triweekly carboplatin)
Number of subjects: 40
Study 32224896 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-Carboplatin
Number of subjects: 40
Study 32224896 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Cisplatin and Paclitaxel-Carboplatin
Number of subjects: 40
Study 32224896 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy duration >21 weeks
Number of subjects: 40
Study 32224896 — intervention group
Group type: EXPERIMENTAL
Intervention: Suboptimal debulking surgery (>1 cm)
Number of subjects: 40
Study 35833082 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Xiaochaihu Decoction combined with mirtazapine
Number of subjects: 64
Study 35833082 — intervention group
Group type: COMPARATOR
Intervention: Modified Xiaochaihu Decoction (control group)
Number of subjects: 64
Study 33183752 — intervention group
Group type: EXPERIMENTAL
Intervention: N-Hexyl Cyanoacrylate glue
Number of subjects: 58
Study 33183752 — intervention group
Group type: COMPARATOR
Intervention: Sutures
Number of subjects: 58
Study 36401493 — intervention group
Group type: EXPERIMENTAL
Intervention: ORi-SpO2 group (FiO2 adjusted to target 0 < 0 ORi < .3 and SpO2 ≥ 98%)
Number of subjects: 62
Study 36401493 — intervention group
Group type: COMPARATOR
Intervention: SpO2 group (FiO2 adjusted to target SpO2 ≥ 98%)
Number of subjects: 62
Study 36401493 — intervention group
Group type: COMPARATOR
Intervention: SpO2 group
Number of subjects: 62
Study 36401493 — intervention group
Group type: EXPERIMENTAL
Intervention: ORi-SpO2 group
Number of subjects: 62
Study 32717868 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous-intensity physical exercise program (2 hours per week)
Number of subjects: 98
Study 32717868 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 98
Study 36441999 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Families Now (TFN) or Children in Between (CIB)
Number of subjects: 221
Study 36441999 — intervention group
Group type: COMPARATOR
Intervention: No-program control group
Number of subjects: 221
Study 34009517 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 30
Study 34009517 — intervention group
Group type: EXPERIMENTAL
Intervention: Micropulse Cyclophotocoagulation (MP-CPC)
Number of subjects: 30
Study 34009517 — intervention group
Group type: EXPERIMENTAL
Intervention: Transscleral Continuous-Wave Cyclophotocoagulation (CW-CPC)
Number of subjects: 30
Study 36115088 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and Lifestyle Education (ExLE; 12-week exercise and educational interventions)
Number of subjects: 0
Study 36115088 — intervention group
Group type: COMPARATOR
Intervention: Exercise (Ex; 12-week exercise intervention only)
Number of subjects: 0